Cosar Pharmaceutical Company was established in 1973 under the name Chemico Pharmaceutical Company. At that time, the company’s product portfolio consisted of oral antibiotic pharmaceutical products produced under the license of Beecham Pharmaceuticals, UK. Over time, with the establishment of new production lines for non-antibiotic oral solid drugs, other generic products, supplements, and natural products in the forms of tablets, capsules, sachets, syrups, and bulk powders were added to the company’s product portfolio. In 2021, a new production line for oral solid drugs with a Level 3 and 3 Plus exposure category was added to the company’s production lines for the production of central nervous system drugs and some new drugs subject to these requirements. Additionally, with the efforts of the company’s specialists, it is anticipated that the company’s first biosimilar drug will enter the market in 2023